ResMed (RMD.AX ASX) Q2 beats lift A$36.82 intraday 30 Jan 2026: watch margins

RMD.AX stock jumped after ResMed Inc. reported stronger Q2 results, confirming demand for sleep and respiratory devices. The company posted GAAP earnings of A$392.59 million and EPS of A$2.68, with revenue up to A$1.422 billion, a 10.90% year-on-year increase. Intraday on 30 Jan 2026 the ASX-listed share is trading at A$36.82, range A$36.67–A$37.17, with volume 850344.00. Investors should watch margin trends and software subscription growth for signs of sustainable earnings momentum.